Shannon M Mumenthaler, PhD

Dr. Mumenthaler is an Assistant Professor of Research Medicine at the CAMM. She received a B.S. in Genetics from UC Davis and a Ph.D. in Cellular and Molecular Pathology from UCLA. Although her primary scientific training is in cell biology, Dr. Mumenthaler applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians, and engineers to explore critical areas in cancer. Her current research interests focus on the development of tools to better understand the evolutionary dynamics of tumor progression and drug resistance with specific investigations into the influence of microenvironmental selective pressures on tumor cell behavior. Toward this goal, Dr. Mumenthaler is closely collaborating with mathematical modelers to combine novel computational platforms with diverse experimental measurements to test and refine biological hypotheses and make clinically relevant predictions.

• USC: Medical Faculty Women’s Association Award, 2013
• National Cancer Institute: Junior Investigator Award, 2013
• Third Annual National Cancer Institute Physical Sciences in Oncology Center: Best Poster Award, 2012
• University of California, Los Angeles: Hortenese Fishbaugh Memorial Scholarship, 2006-2007
• University of California, Los Angeles: Life Sciences Core Curriculum Teaching Assistant Honorarium Award, 2005-2006
• University of California, Davis: Graduated with Honors, 2003
• University of California, Davis: Undergraduate Student of the Year Award, Division of Biological Sciences, 2003
• University of California, Davis: Howard Hughes Medical Institute Summer Honors Advanced Research Program (SHARP) Fellowship, 2002
• University of California, Davis: Alumni Scholarship, 2000
• Webber Foundation: Academic Scholarship, 1999-2003

• Integration of Patient-Derived Organoids and Organ-on-Chip Systems: Investigating Colorectal Cancer Invasion within the Mechanical and GABAergic Tumor Microenvironment bioRxiv. 2023 Sep 17. . View in PubMed
• Organs-on-chips: a decade of innovation Trends Biotechnol. 2023 03; 41(3):278-280. . View in PubMed
• Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions Oncogene. 2023 02; 42(9):627-637. . View in PubMed
• Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data Cell Rep Methods. 2023 03 27; 3(3):100417. . View in PubMed
• Phosphorylation and stabilization of EZH2 by DCAF1/VprBP trigger aberrant gene silencing in colon cancer Nat Commun. 2023 04 17; 14(1):2140. . View in PubMed
• Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment Oncogene. 2022 10; 41(43):4769-4778. . View in PubMed
• Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer Br J Cancer. 2022 01; 126(1):72-78. . View in PubMed
• Elucidating tumor-stromal metabolic crosstalk in colorectal cancer through integration of constraint-based models and LC-MS metabolomics Metab Eng. 2022 01; 69:175-187. . View in PubMed
• Roadmap on plasticity and epigenetics in cancer Phys Biol. 2022 04 18; 19(3). . View in PubMed
• Reprogramming CBX8-PRC1 function with a positive allosteric modulatorCell Chem Biol. 2022 04 21; 29(4):555-571. e11. . View in PubMed
• Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread iScience. 2021 May 21; 24(5):102509. . View in PubMed
• VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer Mol Oncol. 2021 10; 15(10):2801-2817. . View in PubMed
• 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration Clin Transl Sci. 2021 09; 14(5):1659-1680. . View in PubMed
• RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC Mol Cancer Ther. 2021 06; 20(6):1153-1160. . View in PubMed
• Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer Eur J Cancer. 2021 06; 150:133-142. . View in PubMed
• Clocking cancer: the circadian clock as a target in cancer therapy Oncogene. 2021 05; 40(18):3187-3200. . View in PubMed
• High-throughput microscopy reveals the impact of multifactorial environmental perturbations on colorectal cancer cell growth Gigascience. 2021 04 19; 10(4). . View in PubMed
• Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response Front Oncol. 2021; 11:771173. . View in PubMed
• Impact of tumor-parenchyma biomechanics on liver metastatic progression: a multi-model approach Sci Rep. 2021 01 18; 11(1):1710. . View in PubMed
• Multiplexed imaging and effluent analysis to monitor cancer cell intravasation using a colorectal cancer-on-chip STAR Protoc. 2021 12 17; 2(4):100984. . View in PubMed
• Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance Cancers (Basel). 2020 May 28; 12(6). . View in PubMed
• Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer J Immunother Cancer. 2020 11; 8(2). . View in PubMed
• Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response SLAS Discov. 2020 08; 25(7):744-754. . View in PubMed
• A Perspective on Expanding Our Understanding of Cancer Treatments by Integrating Approaches from the Biological and Physical Sciences SLAS Discov. 2020 08; 25(7):672-683. . View in PubMed
• Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 Eur J Cancer. 2019 04; 111:138-147. . View in PubMed
• AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 Int J Cancer. 2019 10 15; 145(8):2082-2090. . View in PubMed
• A truncating mutation in the autophagy gene UVRAG drives inflammation and tumorigenesis in mice Nat Commun. 2019 12 12; 10(1):5681. . View in PubMed
• MALDI Mass Spectrometry Imaging for Evaluation of Therapeutics in Colorectal Tumor Organoids J Am Soc Mass Spectrom. 2018 03; 29(3):516-526. . View in PubMed
• PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems PLoS Comput Biol. 2018 02; 14(2):e1005991. . View in PubMed
• mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer Cancer Lett. 2018 10 10; 434:152-159. . View in PubMed
• MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures Anal Chem. 2018 12 18; 90(24):14156-14164. . View in PubMed
• Image-Based Tracking of Heterogeneous Single-Cell Phenotypes Methods Mol Biol. 2018; 1745:47-63. . View in PubMed
• Characterization of the mechanical properties of resected porcine organ tissue using optical fiber photoelastic polarimetry Biomed Opt Express. 2017 Oct 01; 8(10):4663-4670. . View in PubMed
• Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques J Vis Exp. 2017 06 30; (124). . View in PubMed
• Quantifying differences in cell line population dynamics using CellPD BMC Syst Biol. 2016 Sep 21; 10(1):92. . View in PubMed
• Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors PLoS Comput Biol. 2016 08; 12(8):e1005077. . View in PubMed
• Dual transcript and protein quantification in a massive single cell array Lab Chip. 2016 10 07; 16(19):3682-8. . View in PubMed
• Progress Towards Computational 3-D Multicellular Systems Biology Adv Exp Med Biol. 2016; 936:225-246. . View in PubMed
• Significance of duon mutations in cancer genomes Sci Rep. 2016 06 08; 6:27437. . View in PubMed
• A high-content image-based method for quantitatively studying context-dependent cell population dynamics Sci Rep. 2016 07 25; 6:29752. . View in PubMed
• Single cell dynamic phenotyping Sci Rep. 2016 10 06; 6:34785. . View in PubMed
• Predictive Modeling of Drug Response in Non-Hodgkin’s Lymphoma PLoS One. 2015; 10(6):e0129433. . View in PubMed
• Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance Biomarkers. 2015; 20(5):313-22. . View in PubMed
• The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells Cancer Inform. 2015; 14(Suppl 4):19-31. . View in PubMed
• Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments Mol Cancer Ther. 2014 Nov; 13(11):2607-17. . View in PubMed
• Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors Evol Appl. 2013 Jan; 6(1):54-69. . View in PubMed
• The Need for Integrative Computational Oncology: An Illustrated Example through MMP-Mediated Tissue Degradation Front Oncol. 2013; 3:194. . View in PubMed
• A physical sciences network characterization of non-tumorigenic and metastatic cells Sci Rep. 2013; 3:1449. . View in PubMed
• Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer Mol Pharm. 2011 Dec 05; 8(6):2069-79. . View in PubMed
• Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes Mol Cancer Ther. 2009 Oct; 8(10):2882-93. . View in PubMed
• 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice J Cardiovasc Transl Res. 2009 Sep; 2(3):289-99. . View in PubMed
• CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function Virology. 2009 Apr 25; 387(1):59-66. . View in PubMed
• Disruption of arginase II alters prostate tumor formation in TRAMP mice Prostate. 2008 Oct 01; 68(14):1561-9. . View in PubMed
• Expression of arginase II in prostate cancer Int J Oncol. 2008 Feb; 32(2):357-65. . View in PubMed

• Lenz, Heinz-Josef
• Zhang, Lin